Medical Cannabis Technology Company Signs Deals in Canada and U.S.

TORONTO, Oct. 31, 2017 (GLOBE NEWSWIRE) -- In a deal expected to disrupt the Canadian market, Resolve Digital Health Inc. (“Resolve”), a Canadian developer of intelligent medical cannabis delivery devices, has concluded an exclusive agreement with Aphria Inc. (“Aphria”), one of Canada’s largest licensed producers of medical cannabis. 

Under the agreement, Aphria will provide cannabis products to fill Resolve’s proprietary delivery pods and cartridges for sale to the Canadian medical cannabis market.  

Rob Adelson, CEO of Resolve said: “This agreement allows Resolve to take a significant step towards launching the first of our Breeze Smart Inhalers^TM domestically. Both organizations have impressive growth trajectories, and combining Resolve’s innovative technology with Aphria’s high-quality medical cannabis will allow us to disrupt the Canadian market.”

Breeze Smart Inhalers use machine-learning algorithms to provide patients with the dosing and strain selection most appropriate to their medical condition. The device captures data on medical conditions, prescriptions, family history, lifestyle, and effectiveness per dose, and uses that data to monitor treatment efficacy and continuously improve the medical cannabis experience for patients.

Vic Neufeld, CEO of Aphria and Chairman of the Board for Liberty Health Sciences Inc. (“Liberty”), said: “Aphria is delighted to partner with Resolve in Canada. This agreement is consistent with both companies’ commitment to leading in the space, and to bringing safe and effective cannabis products as part of a holistic medical cannabis ecosystem for Canadian patients.”

In the US, medical cannabis sales are projected to grow from $4.7 billion in 2016 to $13.3 billion in 2020.¹ In Canada alone, the patient population using medical cannabis for various indications is growing at a pace of more than 10,000 new patients per month, and reached 201,398 in June 2017,² a 268 per cent increase from the 75,166 registered at the end of June 2016.²

Across a growing number of jurisdictions, medical cannabis is being prescribed to help relieve chemotherapy-induced nausea and vomiting, as well as pain associated with cancer, and the management of chronic pain, arthritis and joint disorders, multiple sclerosis (MS), fibromyalgia and migraines. 

Partnership with Liberty Health Sciences Inc. in Florida
Resolve’s deal with Aphria adds to a major partnership, announced on October 11^th, with Liberty, an investor and operator in the medical cannabis market. Another important step in enhancing the medical cannabis patient experience, Liberty gains exclusive distribution rights to Resolve products within the state of Florida (subject to Florida Department of Health and Office of Medical Marijuana Use approvals). Adelson added: “These partnerships clearly signify our ambition to become a leader in the medical cannabis space throughout North America, leaving us in a great position for sustained growth.” 

About Resolve Digital Health
Resolve Digital Health is positioned to be the leading provider of a metered dosing ecosystem for medical cannabis devices. The company's proprietary technology, apps and cloud-based health information platform, found in Resolve's debut product Breeze, address the numerous issues with currently available methods of cannabis delivery – establishing a standard of care and rigorous medical approach for the medical cannabis industry. With over three years of research and development, the complete product ecosystem will be initially available in select dispensaries in early 2018. For more information, visit: www.mybreeze.co or www.resolvedigitalhealth.com.

About Aphria
Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis.  Located in Leamington, Ontario, the greenhouse capital of Canada.  Aphria is truly powered by sunlight, allowing for the most natural growing conditions available.  We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. www.aphria.com

About Liberty Health Sciences Inc.
Liberty Health Sciences Inc. (“Liberty”) is an investor and operator in the medical cannabis market, capitalizing on new and existing opportunities in U.S. states where medical cannabis is legal.  Liberty’s stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near and mid-term opportunities.  Liberty has an extensive background in highly regulated industries, with expertise in becoming a low-cost producer.  Liberty leverages commercial greenhouse knowledge to deliver high-quality, clean and safe pharmaceutical grade cannabis to patients. www.libertyhealthsciences.com

For more information:

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: Certain information in this news release constitutes “forward-looking information” and “forward-looking statements” under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “projections”, “expect”, “believe”, “plan”, “intend”, “estimated” or the negative of these terms and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Resolve, Aphria, Liberty or the collaboration between Resolve, Aphria and Liberty to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Examples or such forward-looking information includes, but is not limited to, statements with respect to the anticipated benefits of the collaboration between Resolve, Aphria and Liberty, the receipt of third-party, regulatory and stock exchange approvals, the timeline for the availability of Resolve’s product lines, and the timeline for implementation. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of either party to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking information included in this news release are made as of the date of this news release and Resolve or Aphria or Liberty does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

References:

1. Borchardt, Debra. Forbes Magazine. February 22, 2017. Marijuana Industry Projected To Create More Jobs Than Manufacturing By 2020. https://www.forbes.com/sites/debraborchardt/2017/02/22/marijuana-industry-projected-to-create-more-jobs-than-manufacturing-by-2020/#7686d4c53fa9. Accessed on October 20, 2017.
    
2. Statistics Canada. Access to Cannabis for Medical Purposes Regulations. Market Data. https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-use-marijuana/licensed-producers/market-data.html Accessed on October 20, 2017.